Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
6. New Treatment Significantly Improves Long-Term Outlook for Breast Cancer Survivors:
International clinical trial concludes women should consider taking letrozole after five years of tamoxifen treatment to continue to reduce risk of recurrence
(Posted: 10/09/2003, Updated: 06/10/2004) - A Canadian-led international clinical trial has found that post-menopausal survivors of early-stage breast cancer who took the drug letrozole after completing an initial five years of tamoxifen therapy had a significantly reduced risk of cancer recurrence compared to women taking a placebo.
7. First Evidence That Chemotherapy Extends Life in Advanced Prostate Cancer
(Posted: 06/07/2004) - Chemotherapy regimens that include the drug docetaxel extend median survival by two to three months in patients with advanced prostate cancer that is no longer responsive to hormone therapy, two large phase III studies have shown. These are the first clinical trials to show that chemotherapy can improve survival in advanced prostate cancer.
8. Adding Temozolomide (Temodar®) to Radiation Increases Survival in Glioblastoma Multiforme
(Posted: 06/07/2004) - Adding the drug temozolomide (Temodar®) to radiation therapy for the treatment of a brain tumor called glioblastoma multiforme increased survival in a large randomized trial conducted in Canada and Europe. While this approach has been customary in the United States for several years, these findings are definitive and should establish this approach as the standard of care.
9. Carboplatin May Be Less Toxic Than Radiation for Seminoma
(Posted: 06/07/2004) - One course of carboplatin appeared to be as effective as radiation therapy in treating early seminoma, a kind of testicular cancer, and also appeared safer, reducing the risk of second cancers. Further follow-up is needed to show whether the benefits continue longer than three years.
10. Longer-Term Data Confirm Raloxifene Reduces the Risk of Breast Cancer in Older Women
(Posted: 06/06/2004) - Raloxifene (Evista®) substantially reduced the risk of invasive breast cancer in postmenopausal women with osteoporosis who took the drug for eight years, according to findings presented at the 2004 ASCO meeting in New Orleans. It is not clear whether all women at risk for breast cancer would receive a similar protective benefit.
< Previous 1 2 3 4 5 Next >
|
